TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Juice Concentrate (FVJC)
Description: Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Juice Concentrate (FVJC)
Description: Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
Study: NCT03771950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early team based neuro-rehabilitation
Description: A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
Study: NCT02838264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
Study: NCT04904874

Intervention type: DEVICE
Group type: OTHER
Intervention: intense pulsed light
Description: treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
Study: NCT00133601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
Study: NCT02632097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein Hernioplasty with Sutures
Description: Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
Study: NCT02838264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
Study: NCT03618576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance specific exercise
Description: Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
Study: NCT03796858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: Participants will receive guselkumab 100mg as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: Participants will receive guselkumab 100mg as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo as SC injection.
Study: NCT03223025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CinnaTropin®
Description: 0.03 mg/kg daily subcutaneous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CinnaTropin®
Description: 0.03 mg/kg daily subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nordilet®
Description: 0.03 mg/kg daily subcutaneous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nordilet®
Description: 0.03 mg/kg daily subcutaneous injections
Study: NCT03604016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil
Description: Besifovir dipivoxil 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Besifovir dipivoxil 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide 25mg
Study: NCT01697631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) before lunch
Study: NCT01267682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Description: Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
Study: NCT02213965

Intervention type: DEVICE
Intervention: Peripheral IV catheter
Description: Intravenous access according to Instructions For Use

Intervention type: DEVICE
Intervention: Peripheral IV catheter
Description: Intravenous access according to Instructions For Use
Study: NCT01820169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ;Accu-Chek Compact Plus LCM bulk Japan
Description: HbA1c would be changed by more careful control in blood glucose with SMBG.
Study: NCT01348464

Intervention type: PROCEDURE
Intervention: single port appendectomy, three port appendectomy
Description: visual analog scale. questionnaire on wound satisfaction
Study: NCT00703729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Compression (CC)
Description: The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Wrap (IW)
Description: The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
Study: NCT04123145

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron status testing
Description: Iron status testing
Study: NCT03193918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
Study: NCT00757055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active treatment given
Study: NCT00782054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provase
Description: NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control moisturizer
Description: Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
Study: NCT02386137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhancement ultrasound with Sonovue
Study: NCT03895814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Step Training
Description: Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
Study: NCT04513392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
Study: NCT03744247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenously every 2 weeks
Study: NCT03995277

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin
Description: Daily intake of 10 mg or 50 µg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin
Description: Daily intake of 10 mg or 50 µg per day
Study: NCT00264576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine
Study: NCT04531007

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iFR/ FFR/ IVUS/ OCT
Description: intermediate lesion evaluation with intracoronary physiology and imaging
Study: NCT02980432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changes in whole-body roll position and visual/haptic stimuli presented
Description: In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
Study: NCT02470312

Intervention type: PROCEDURE
Intervention: CRT implantation
Description: It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment

Intervention type: DEVICE
Intervention: MediGuide

Intervention type: DEVICE
Intervention: MediGuide
Study: NCT02838264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral dose of itraconazole on Days 1 to 11 during Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral dose of itraconazole on Days 1 to 11 during Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
Study: NCT03995277

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin
Description: Daily intake of 10 mg or 50 µg per day
Study: NCT03817645

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zeolite
Description: The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
Study: NCT03932396

Intervention type: OTHER
Intervention: Observational study
Description: No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
Study: NCT02470312

Intervention type: PROCEDURE
Intervention: EP
Study: NCT00700557

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics - Lactobacillus casei and Bifidobacterium breve
Description: Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maize starch
Description: Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
Study: NCT00753337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assurant® Cobalt Iliac Stent System
Description: Iliac Stenting
Study: NCT03733574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: Drug: LY03005 80 mg, oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: Drug: LY03005 80 mg, oral tablets, single dose
Study: NCT03817645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeolite
Description: The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
Study: NCT01259479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Orally, once daily for 5 days repeated every 28 days, dose-escalation
Study: NCT04499469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spreader Graft
Description: To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
Study: NCT03733574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: Drug: Pristiq 50 mg, oral tablets, single dose
Study: NCT03309501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tong-Luo-Qu-Tong Plaster
Description: for 14 days as two period of treatment, daily 1 time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qi-Zheng-Xiao-Tong Plaster
Description: for 14 days as two period of treatment, daily 1 time
Study: NCT01044550

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow up
Description: Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
Study: NCT01494116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 900 mL of 0.9% Normal Saline
Description: The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.
Study: NCT01380743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvoglustat
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvoglustat
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvoglustat
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvoglustat
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGAA
Description: Single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGAA
Description: Single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGAA
Description: Single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGAA
Description: Single intravenous infusion
Study: NCT05706688

Intervention type: PROCEDURE
Intervention: Anesthetic technique (regional versus general)
Description: Anesthetic technique (regional versus general)

Intervention type: PROCEDURE
Intervention: Anesthetic technique (regional versus general)
Description: Anesthetic technique (regional versus general)
Study: NCT02626143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational nutrient-rich whey protein formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk based formula
Study: NCT00461695

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccination against TBEV (FSME Immun CC)
Description: Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccination against TBEV (FSME Immun CC)
Description: Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
Study: NCT04213456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Sport Formula
Description: Powder added to water,high protein and multi vitamins and minerals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water), without added vitamins and minerals.
Study: NCT03681457

Intervention type: DRUG
Group type: OTHER
Intervention: LJN452
Description: Dose A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Dose A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Dose A single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Dose A single dose
Study: NCT00579826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
Study: NCT02048553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-guided ventriculostomy
Description: In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand ).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freehand
Description: Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
Study: NCT03243812

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling will be performed to assess hematological and hemorheological parameters
Study: NCT04894136

Intervention type: PROCEDURE
Intervention: ICSI-TESE; embryo-transfer
Description: The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.